Grashma Vadakkel, PharmD, BCOP

Axatilimab is a colony-stimulating factor-1 receptor–blocking monoclonal antibody indicated after 2 lines of systemic therapy.

Treatment selection includes patient factors, cost, adverse effects, and drug interactions.

Treatment often involves a combination of preventive measures, topical therapies, and systemic treatments.

Current guidelines recommend a backbone of SLGT2 therapy in patients with HFpEF who have no contraindications.